Cyclo Stock Based Compensation To Revenue from 2010 to 2024
| CYTH Stock | USD 0.64 0.04 5.88% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.68460756 | Current Value 0.72 | Quarterly Volatility 0.23095546 |
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
Cyclo | Stock Based Compensation To Revenue |
Latest Cyclo Therapeutics' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Cyclo Therapeutics over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Cyclo Therapeutics' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Cyclo Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.26 | |
| Geometric Mean | 0.16 | |
| Coefficient Of Variation | 90.51 | |
| Mean Deviation | 0.19 | |
| Median | 0.11 | |
| Standard Deviation | 0.23 | |
| Sample Variance | 0.05 | |
| Range | 0.6989 | |
| R-Value | 0.67 | |
| Mean Square Error | 0.03 | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | 0.03 | |
| Total Sum of Squares | 0.75 |
Cyclo Stock Based Compensation To Revenue History
About Cyclo Therapeutics Financial Statements
Investors use fundamental indicators, such as Cyclo Therapeutics' Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Cyclo Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.68 | 0.72 |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out the analysis of Cyclo Therapeutics Correlation against competitors. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.